Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025 - 30/07/25

Doi : 10.1016/j.ando.2025.102432

VATIER Camille ^a,^b, ARAUJO-VILAR David ^c, AKINCI Baris ^d, ARNOULD Thierry ^e, BEAUPERE Carine ^b, BISMUTH Elise ^f, J. BROWN Rebecca ^g, CECCARINI Giovanni ^h, COLLAS Philippe ^i,^j, GAMBINERI Alessandra ^k, GILIO Donatella ^h, HALPERIN Sharon ^l, JANMAAT Sonja ^a, LAMOTHE Sophie ^a, LATTANZI Giovanna ^m,ⁿ, MAFFEI Margherita ^o, A. MACDOUGALD Ormond ^p, MOSBAH Héléna ^q, NOBECOURT Estelle ^r, A. ORAL Elif ^s, ROCHFORD Justin ^t, SANTINI Ferruccio ^h, C. SCHIRMER Eric ^u, VON SCHNURBEIN Julia ^v, SEMPLE Robert ^w, TEWS Daniel ^v, WABITSCH Martin ^v, VANTYGHEM Marie-Christine ^x, VIGOUROUX Corinne ^a,^b,⁎
^a Assistance Publique–Hôpitaux de Paris (AP-HP), Saint–Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France
^b Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France
^c UETeM-Molecular Pathology Group, Department of Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain
^d DEPARK, Dokuz Eylul University Health Campus & Izmir Biomedicine and Genome Center (IBG), Izmir, Turkey
^e Laboratory of Biochemistry and Cell Biology (URBC), NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, Belgium
^f Assistance Publique-Hôpitaux de Paris, Robert-Debré University Hospital, Department of Pediatric Endocrinology and Diabetology, Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris-Cité University, European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France
^g National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
^h Obesity and Lipodystrophy Center, Department of Clinical and Experimental Medicine, Endocrinology Unit, University Hospital of Pisa, European Reference Network for Rare Endocrine Conditions (Endo-ERN), and European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), Pisa, Italy
ⁱ Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Norway
^j Department of Immunology and Transfusion Medicine, Oslo University Hospital, Norway
^k Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, European Reference Network for Rare Endocrine Conditions (Endo-ERN), Bologna, Italy
^l Lipodystrophy United, USA
^m University of Bologna, CNR-National Research Council of Italy, Institute of Molecular Genetics « Luigi Luca Cavalli-Sforza » Unit of Bologna, Bologna, Italy
ⁿ IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
^o Institute of Clinical Physiology, National Research Council, National Institute of Nuclear Physics (INFN), Pisa, Italy
^p Department of Molecular & Integrative Physiology, and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
^q Department of Endocrinology, University Hospital La Milétrie, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Poitiers, France
^r University Hospital of Nancy, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Nancy, France
^s Division of Metabolism, Endocrinology & Diabetes and Caswell Diabetes Institute, University of Michigan, Ann Arbor, MI, USA
^t The Rowett Institute and Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Aberdeen, United Kingdom
^u Institute of Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom
^v Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, European Reference Network for Rare Endocrine Conditions (Endo-ERN), Ulm, Germany
^w Centre for Cardiovascular Science, MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, United Kingdom
^x Department of Endocrinology-Metabolism, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Lille University Hospital, and Inserm U1190 - EGID, Institut Pasteur de Lille, Lille University, Lille, France

^⁎Corresponding author: Faculté de Médecine Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, Paris Cedex 75571, FranceFaculté de Médecine Sorbonne Université, Site Saint-Antoine, 27 rue ChalignyParis Cedex75571France

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Wednesday 30 July 2025
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

ABSTRACT

Lipodystrophy syndromes are rare diseases characterized by anatomical and functional defects of adipose tissue, frequently leading to severe insulin resistance-associated metabolic complications. Subtypes of lipodystrophy syndromes differ in: their clinical presentation, with generalized or partial loss of adipose tissue; in their origin, either genetic or acquired; and in their comorbidities, forming a heterogeneous group of disorders of different severity. The European Consortium of Lipodystrophies (ECLip) was founded in 2014 as a non-profit network of health professionals, scientists and patient associations. ECLip aims to promote international collaborations to increase pathophysiological and clinical knowledge, and improve the management of lipodystrophy syndromes. ECLip now comprises 59 groups from 30 countries from Europe and beyond. The consortium developed in parallel to the increased awareness of clinical diagnosis, the growing scientific interest for these diseases at the crossroads between adipose tissue biology, whole body metabolism, genetics and immunity, and to the emergence of new pharmacological approaches. The ECLip congress, held every 18 months, aims to discuss the recent achievements and projects in the field of lipodystrophies, to consolidate ECLip activities and to promote future collaborations, highlighting clinical and fundamental aspects as well as patients’ perspectives. Oral communications presented during the meeting in Paris, France, in 2025 are summarized in these minutes.

Le texte complet de cet article est disponible en PDF.

Keywords : Lipodystrophy, Laminopathies, Adipocytes, Cardiovascular disease, Seipin, Mitochondria, Registry, Natural history, Leptin, Quality of life, POLD1, Cellular senescence, Caveolin-1, Therapies, Epidemiology, Auto-immunity, Diet, Lipidomic, Chromatin, Metabolism

Export

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025 - 30/07/25

ABSTRACT

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL